Merck says research shows its Covid-19 pill works against variants
Laboratory studies show that Merck & Co's experimental oral Covid-19 antiviral drug, molnupiravir, is likely to be effective against known variants of the coronavirus, the company said on Wednesday.
They said this includes the dominant, highly transmissible Delta.
Since molnupiravir does not target the spike protein of the virus - the target of all current Covid-19 vaccines...
Verifying user
RM12.50 / month
- Unlimited access to award-winning journalism
- Comment and share your opinions on all our articles
- Gift interesting stories to your friends
- Tax deductable